1190389-15-1

Basic information

• Product Name: MB-07133
• Synonyms: (6S)-4,6,7,8-Tetrahydro-N-[4-[[(2S,5R)-5-[(R)-hydroxyphenylmethyl]-2-pyrrolidinyl]methyl]phenyl]-4-oxopyrrolo[1,2-a]pyrimidine-6-carboxamide
• CAS NO: 1190389-15-1
• Molecular Formula: C₂₆H₂₈N₄O₃
• Molecular Weight: 444.52552
• Mol File: 1190389-15-1.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• Density: 1.36±0.1 g/cm3(Predicted)
• PKA: 13.55±0.70(Predicted)
• CAS DataBase Reference: MB-07133(CAS DataBase Reference)
• NIST Chemistry Reference: MB-07133(1190389-15-1)
• EPA Substance Registry System: MB-07133(1190389-15-1)

Safety Data

• Hazardous Substances Data: 1190389-15-1(Hazardous Substances Data)

Usage

Description

MB-07133 is a chemical compound with specific properties that make it suitable for various applications across different industries.

Uses

Used in Pharmaceutical Industry:
MB-07133 is used as a potent and selective β3 Adrenergic receptor agonist for the treatment of overactive bladder. Its mechanism of action involves stimulating the β3 receptors, leading to relaxation of the smooth muscles in the bladder and improving symptoms associated with overactive bladder conditions.
Used in Chemical Research:
MB-07133 can be utilized as a research tool in the development of new drugs and therapies targeting the β3 Adrenergic receptor. Its selectivity and potency make it a valuable compound for studying the receptor's role in various physiological processes and for identifying potential therapeutic agents.
Used in Drug Formulation:
MB-07133 can be incorporated into pharmaceutical formulations as an active ingredient for the management of overactive bladder symptoms. It may be combined with other therapeutic agents or excipients to create effective treatments that address the specific needs of patients with this condition.

Upstream product

• 2767-70-6 (p-nitrobenzyl)triphenylphosphonium bromide 
• 1190391-85-5 (2S,5R)-tert-butyl 2-(4-aminobenzyl)-5-((R)-hydroxy(phenyl)methyl)pyrrolidine-1-carboxylate 
• 1190392-23-4 methyl [6(S)-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-α]]pyrimidine-6-carboxylate 
• 1426235-09-7 C₁₂H₁₇NO₂ 
• 1009092-91-4 tert-butyl (4R,5R)-4-(hydroxymethyl)-2,2-dimethyl-5-phenyl-1,3-oxazolidine-3-carboxylate 
• 46032-98-8 (1R,2R)-2-amino-1-phenylpropane-1,3-diol 
• 4931-66-2 methyl (S)-pyroglutamate 
• 1295539-30-8 (R)-((2R,5S)-5-(4-aminobenzyl)pyrrolidin-2-yl)(phenyl)methanol 
• 1426235-02-0 C₃₁H₄₂N₂O₆ 
• 1190391-89-9 tert-butyl (4R,5R)-2,2-dimethyl-4-[4-(4-nitrophenyl)but-3-en-1-yl]-5-phenyl-1,3-oxazolidine-3-carboxylate 
• 1190391-88-8 (4R,5R)-2,2-dimethyl-4-(3-oxopropyl)-5-phenyl-3-oxazolidinecarboxylic acid 1,1-dimethylethyl ester 
• 1190391-87-7 tert-butyl (4R,5R)-2,2-dimethyl-4-[(1E)-3-oxoprop-1-en-1-yl]-5-phenyl-1,3-oxazolidine-3-carboxylate 
• 1190709-67-1 methyl (7S)-9-oxo-3,8-diazatetracyclo[9.2.1.0(2,10).0(4,8)]tetradeca-3,12-diene-7-carboxylate 
• 173142-47-7 methyl (2S)-5-methoxy-3,4-dihydro-2H-pyrrole-2-carboxylate 

Relevant articles and documents

Synthesis of Vibegron Enabled by a Ketoreductase Rationally Designed for High pH Dynamic Kinetic Reduction

Described here is an efficient stereoselective synthesis of vibegron enabled by an enzymatic dynamic kinetic reduction that proceeds in a high-pH environment. To overcome enzyme performance limitations under these conditions, a ketoreductase was evolved by a computationally and structurally aided strategy to increase cofactor stability through tighter binding.

PROCESS FOR PREPARING BETA 3 AGONISTS AND INTERMEDIATES

The application is directed to efficient and economical processes as described in more detail below for the preparation of the beta 3 agonists of the formula of I-7 and intermediate compounds that can be used for making these agonists. The present disclosure relates to a process for making beta-3 agonists and intermediates using ketoreductase (KRED) biocatalyst enzymes and methods of using the biocatalysts.

COMBINATION THERAPY USING A BETA 3 ADRENERGIC RECEPTOR AGONIST AND AN ANTIMUSCARINIC AGENT

Described herein is an improved method of treating overactive bladder, wherein the method comprises administering to a patient in need thereof a beta 3 adrenergic receptor agonist, an antimuscarinic agent, and an optional selective M2 antagonist. Such combination therapy provides improved efficacy and/or reduced side effects.